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AIDS 2016, 30:969–974Strengthening universal HIV ‘test-and-treat’ approaches with social science researchThe recent publication of new WHO guidelines,
including a call for antiretroviral therapy for everyone
diagnosed with HIV regardless of CD4þ cell count and
preexposure prophylaxis for people at substantial risk of
HIV infection [1], marks an important moment for taking
stock of what will be needed to take biomedical HIV
prevention approaches to scale, and sustain them. As the
author of a recent editorial in The Lancet [2] observes,
these guidelines are ‘welcome but ambitious. [. . .] No
studies exist that address how such a strategy can be
executed on a global scale’ (p. 1420).
We, a multidisciplinary group of social scientists working
as part of five large-scale ‘universal test-and-treat’ (UTT)
trials being implemented across six African countries,
would argue that successful large-scale expansion of
treatment and preexposure prophylaxis will require an in-
depth understanding of the heterogeneous community
and health systems’ contexts of the rollout.
The Social Science of Universal Test and Treat Network
group met in Kampala in October 2015 to critically
reflect on the role social science plays in supporting the
successful implementation of UTT in African contexts.
These deliberations underlined the complexities of
implementing the new era of treatment and prevention.
Social science work to date and the experience of others
implementing UTT already shows that UTT is not a
biomedical ‘one-size-fits-all’ intervention. It includes
multiple client journeys and repeated activities (such as
testing and adherence) in diverse health systems and social
contexts; moreover, diverse ‘models’ of UTT are
currently being implemented. We cannot control for
the very varied contexts in which antiretroviral therapy
will be delivered, and the unanticipated factors in ‘real-
life’ contexts that can mediate the effects of UTT on
desired outcomes.
Among the early lessons from social science research in
the trials are, for instance, that sex, age, and other
social hierarchies matter, but so do attention to how
taking treatment fits into an individual’s broader (and
dynamic) life experience: addressing uptake, adherence,
and retention will rely upon an understanding of why
men and women delay, start, and stop treatment. Our
UTT data are replete with examples of the dilemmas
faced by individuals navigating each step in the care
cascade, which are shaped, for example, by gendered
power relations within couples. At a study site in Zambia,
for instance, a 20-year-old HIV-positive woman Copyright © 2016 Wolters Kluwe
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that she had not yet gone to the clinic to access HIV
services because she was worried about her husband’s
response to her status. She feared that he might divorce
her if he found out she had HIV. The data we gather
about real dilemmas among people making decisions
about HIV care, in aggregate, inform a broad under-
standing of the ways in which individuals in different
couples, families, and communities can be subject to
pressures that may force them onto testing and treatment
or delay access, as well as affect continued access to care.
Certain populations, such as adolescents, are facing
particularly severe pressures. We are also observing that
migrant and highly mobile individuals, a key margin-
alized yet economically important population, need
tailored interventions to support their access and
sustenance in care, because those who move from place
to place because of work or other factors will
(continually) fall into each of the ‘10%’ not reached by
the 90-90-90 targets. Social science research studies in
the trials are investigating how forms of HIV-related
stigma are changing as a result of UTT, and how these
changes are in turn affecting the trials. Social scientists are
examining how the history of delivery of HIV
interventions in different places affects expectations
and perceptions of HIV-care delivery, and how the
delivery of prompt treatment is fitting within existing,
often overstretched, health systems in Africa – both of
which influence uptake and sustained use of treatment.
We are learning that we need different ways to support
people to accept prompt initiation of treatment if they do
not feel unwell, or have concerns about side-effects or
other factors that affect life and work.
In short, social and behavioral sciences provide crucial
contextual evidence on how treatment and prevention is
implemented and scaled up, and what social and
behavioral consequences and impact of ‘universal’ access
to testing, treatment, and prevention can be expected, and
thus holds valuable lessons for the UTT rollout. We
believe that now is a crucial time to set goals for the
inclusion of social science in the implementation science
research program for delivering high-quality prevention
and treatment across Africa.Acknowledgements
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DOI:10.1097/QAD.0000000000001008Raltegravir is safely used with long-term viral suppression for HIV-infected patients on hemodialysis:
a pharmacokinetic studyThe number of HIV-infected patients receiving
hemodialysis has been remarkably increasing because
of the rise in the prevalence of chronic kidney disease
[1]. Renal dysfunction and the hemodialysis procedure
significantly affect the pharmacokinetics of antiretro-
viral drugs, and dose adjustment and/or change in the
medication schedule are occasionally needed, which
carry a risk of poor adherence and treatment failure.
Raltegravir (RAL) is an integrase inhibitor of HIV. It is
mainly metabolized by uridine diphosphate glucuro-
nosyltransferase 1A1 in the liver, and urinary excretion
is less than 10% [2]. Thus, RAL is considered a better
choice of antiretroviral drug for HIV patients on
hemodialysis.
In this study, we determined serum concentrations of RAL
by high performance liquid chromatography in two HIV-
infected patients undergoing maintenance hemodialysis.
The patients received regular doses of RAL (400 mg) twice
daily both on hemodialysis and nonhemodialysis days in
combination with abacavir and etravirine. This study was
approved by the Ethical Committee of Gunma University
Faculty of Medicine, and written informed consent was
obtained from each patient.
Patient 1 was a 64-year-old man who had been on
maintenance hemodialysis thrice weekly from June 2011because of idiopathic membranous nephropathy. He had
been taking RAL for the previous 2 months before
hemodialysis was initiated. During the year between June
2011 and June 2012, blood sampling was performed on
nine different days: 3 days when hemodialysis was
performed in the morning (a.m.-hemodialysis), 3 days in
the afternoon (p.m.-hemodialysis), and 3 nonhemodia-
lysis days. During each hemodialysis session, blood
samples were collected from the indwelling dialysis
catheter every 1 h. On nonhemodialysis days, venous
blood was drawn at the same time intervals. The patient
took RAL regularly at 08 : 00 and 20 : 00 regardless of
whether hemodialysis was performed. Figure 1a shows
the kinetics of RAL concentrations in patient 1. There
was no difference in the RAL concentrations at each time
point between a.m.-hemodialysis (solid line) and
nonhemodialysis (dotted line) days. Peak values were
reached 3.5 h after taking RAL at comparable levels on
a.m.-hemodialysis and nonhemodialysis days (942.2
and 859.9 ng/ml, respectively). The kinetics of RAL
on the p.m.-hemodialysis days (dashed line) also
fitted with those obtained on a.m.-hemodialysis and
nonhemodialysis days. These results indicated that
hemodialysis had no impact on the pharmacokinetics
of RAL in this patient. Ctrough was 238.6 ng/ml, above
the reference value (14 ng/ml) of IC95 reported
previously [3].ealth, Inc. All rights reserved.
